INO Earnings Date: Nov 10, 2026 (Estimated) — Inovio Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is INO's next earnings date?
Inovio Pharmaceuticals, Inc. (INO) is expected to report earnings on Tuesday, November 10, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.20 on revenue of $2.3M.
How did INO do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Inovio Pharmaceuticals, Inc. posted EPS of -$0.07 versus the -$0.22 estimate, a beat of 72.0%. Revenue was $0 against a $533,333 estimate. The stock's 1-day post-earnings move was +16.9%.
How much does INO stock move after earnings?
INO beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.3% (up or down) in the day after earnings.
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.22 | -0.07 | +72.00% | $0 | ✅ Beat | +16.90% | +68.83% | +62.34% |
| 2026-05-13 | Q1 2026 | -0.32 | -0.28 | +12.50% | $0 | ✅ Beat | +1.49% | -8.21% | -17.91% |
| 2026-03-12 | Q4 2025 | -0.35 | -0.26 | +25.71% | $0 | ✅ Beat | -1.19% | -1.79% | -35.12% |
| 2025-11-10 | Q3 2025 | -0.49 | -0.44 | +10.20% | $0 | ✅ Beat | -6.98% | -7.91% | +0.93% |
| 2025-08-12 | Q2 2025 | -0.62 | -0.61 | +1.61% | $0 | ✅ Beat | +14.09% | +30.20% | +77.85% |
| 2025-03-18 | Q4 2024 | -0.83 | -0.65 | +21.69% | $117,000 | ✅ Beat | -6.67% | -13.81% | -18.10% |
| 2024-11-14 | Q3 2024 | -1.13 | -0.89 | +21.24% | $0 | ✅ Beat | -10.59% | -14.88% | -54.93% |
| 2024-05-13 | Q1 2024 | -1.00 | -1.31 | -31.00% | $0 | ❌ Miss | +0.53% | -2.20% | -16.55% |
Showing last 8 quarters.